Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab.
| dc.contributor.author | Isaacs, James | |
| dc.contributor.author | Welsby, Ian J | |
| dc.contributor.author | Schroder, Jacob N | |
| dc.contributor.author | Onwuemene, Oluwatoyosi A | |
| dc.date.accessioned | 2023-04-07T12:58:18Z | |
| dc.date.available | 2023-04-07T12:58:18Z | |
| dc.date.issued | 2021-11 | |
| dc.date.updated | 2023-04-07T12:58:17Z | |
| dc.description.abstract | In the perioperative management of patients with hemophilia A, emicizumab prevents the accurate measurement of common clotting assays, including the activated clotting time (ACT), which is essential for high-dose heparin monitoring during cardiopulmonary bypass surgery. The authors describe the successful perioperative management of a hemophilia A patient on maintenance emicizumab who, following a non-ST myocardial infarction, underwent cardiopulmonary bypass grafting surgery with heparin monitoring using both the ACT and heparin levels from the Hepcon protamine titration device. Postoperatively, the patient was transitioned to recombinant factor VIII replacement therapy. In hemophilia A patients on emicizumab who require heparin titration on cardiopulmonary bypass surgery, the ACT, combined with Hepcon heparin levels, may be used to complete the surgery successfully without excessive bleeding or morbidity. | |
| dc.identifier | S1053-0770(20)30853-3 | |
| dc.identifier.issn | 1053-0770 | |
| dc.identifier.issn | 1532-8422 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Elsevier BV | |
| dc.relation.ispartof | Journal of cardiothoracic and vascular anesthesia | |
| dc.relation.isversionof | 10.1053/j.jvca.2020.08.058 | |
| dc.subject | Hepcon protamine titration device | |
| dc.subject | activated clotting time | |
| dc.subject | cardiopulmonary bypass surgery | |
| dc.subject | emicizumab | |
| dc.subject | hemophilia A | |
| dc.subject | Antibodies, Bispecific | |
| dc.subject | Antibodies, Monoclonal, Humanized | |
| dc.subject | Anticoagulants | |
| dc.subject | Cardiopulmonary Bypass | |
| dc.subject | Hemophilia A | |
| dc.subject | Heparin | |
| dc.subject | Humans | |
| dc.subject | Plant Preparations | |
| dc.subject | Protamines | |
| dc.subject | Whole Blood Coagulation Time | |
| dc.title | Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Welsby, Ian J|0000-0002-2789-5612 | |
| duke.contributor.orcid | Onwuemene, Oluwatoyosi A|0000-0001-7266-7101 | |
| pubs.begin-page | 3299 | |
| pubs.end-page | 3302 | |
| pubs.issue | 11 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Anesthesiology | |
| pubs.organisational-group | Anesthesiology, Cardiothoracic | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Surgery | |
| pubs.organisational-group | Medicine, Hematology | |
| pubs.organisational-group | Surgery, Cardiovascular and Thoracic Surgery | |
| pubs.publication-status | Published | |
| pubs.volume | 35 |
Files
Original bundle
- Name:
- Emicizumab Revisions Final.docx
- Size:
- 60.52 KB
- Format:
- Unknown data format
- Description:
- Accepted version